
DNLI
Denali Therapeutics Inc.
$15.27
-$0.38(-2.43%)
42
Overall
--
Value
40
Tech
44
Quality
Market Cap
$2.27B
Volume
1.89M
52W Range
$10.57 - $33.33
Target Price
$32.20
Order:
Income Statement
Metric | Trend | Chart | 2018 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
Total Revenue | $129.2M | $335.6M | $48.7M | $105.1M | $330.5M | -- | ||
Total Revenue | $129.2M | $335.7M | $48.7M | $108.5M | $330.5M | -- | ||
GROSS PROFIT | ||||||||
Gross Profit | $129.2M | $335.7M | $48.7M | $108.5M | $330.5M | -- | ||
OPERATING EXPENSES | ||||||||
Operating Expenses | $-175.5M | $272.9M | $344.4M | $449.2M | $527.2M | $501.9M | ||
Research & Development | $143.2M | $212.6M | $265.4M | $358.7M | $423.9M | $396.4M | ||
Research Expense | $143.2M | $212.6M | $265.4M | $358.7M | $423.9M | $396.4M | ||
Selling, General & Administrative | $32.3M | $60.3M | $79.1M | $90.5M | $103.4M | $105.4M | ||
General & Administrative Expenses | $32.3M | $60.3M | $79.1M | $90.5M | $103.4M | $105.4M | ||
Salaries & Wages | $-18.8M | -- | -- | -- | -- | -- | ||
Depreciation & Amortization | $-7.4M | $8.5M | $8.6M | $10.4M | $16.7M | $7.8M | ||
Depreciation & Amortization | $-7.4M | $8.5M | $8.6M | -- | -- | -- | ||
Amortization | -- | -- | -- | -- | -- | $1.2M | ||
Other Operating Expenses | $-1.5M | $-3.0M | $-4.7M | -- | -- | -- | ||
OPERATING INCOME | ||||||||
Operating income | $-46.4M | $62.7M | $-295.8M | $-340.7M | $-196.7M | $-487.3M | ||
EBITDA | $-28.8M | $71.2M | $-287.2M | $-315.6M | $-180.0M | $-492.9M | ||
NON-OPERATING ITEMS | ||||||||
Intinc | $10.1M | -- | -- | -- | $51.5M | $64.6M | ||
Net Non-Operating Interest Income/Expense | $10.1M | -- | -- | $-14.8M | $51.5M | $64.6M | ||
Gain on Sale of Securities | -- | $100.0K | -- | -- | -- | -- | ||
Other Income/Expense | -- | $-9.3M | $-4.6M | $-18.2M | $-51.5M | -- | ||
Other Special Charges | -- | $9.3M | $4.6M | $18.2M | $51.5M | -- | ||
PRE-TAX INCOME | ||||||||
EBIT | $-36.2M | $62.7M | $-295.8M | $-326.0M | $-196.7M | $-501.9M | ||
Pre-Tax Income | $-36.2M | $72.0M | $-291.2M | $-326.0M | $-145.2M | $-422.7M | ||
INCOME TAX | ||||||||
Tax Provision | -- | $823.0K | $-575.0K | $21.0K | $30.0K | $68.0K | ||
NET INCOME | ||||||||
Net Income | $-36.2M | $71.1M | $-290.6M | $-326.0M | $-145.2M | $-422.8M | ||
Net Income (Continuing Operations) | $-36.2M | $71.1M | $-290.6M | $-326.0M | $-145.2M | $-422.8M | ||
Net Income (Discontinued Operations) | $-36.2M | $71.1M | $-290.6M | $-326.0M | $-145.2M | $-422.8M | ||
Net Income (Common Stockholders) | $-36.2M | $71.1M | $-290.6M | $-326.0M | $-145.2M | $-422.8M | ||
TOTALS | ||||||||
Total Expenses | $-175.5M | $272.9M | $344.4M | $449.2M | $527.2M | $501.9M | ||
SHARE & EPS DATA | ||||||||
Average Shares Outstanding | $92.6M | $109.0M | $121.5M | $125.5M | $137.4M | $164.5M | ||
Average Shares Outstanding (Diluted) | $97.7M | $112.7M | $121.5M | $125.5M | $137.4M | $164.5M | ||
Shares Outstanding | $190.6M | $121.0M | $122.8M | $136.7M | $139.2M | $145.2M | ||
Basic EPS | $0.82 | $0.65 | $-2.39 | $-2.6 | $-1.06 | $-2.57 | ||
Basic EPS (Continuing Operations) | -- | $0.65 | $-2.39 | $-2.6 | $-1.06 | $-2.57 | ||
Diluted EPS | $-0.39 | $0.63 | $-2.39 | $-2.6 | $-1.06 | $-2.57 | ||
Diluted EPS (Continuing Operations) | -- | $0.63 | $-2.39 | $-2.6 | $-1.06 | $-2.57 | ||
OTHER METRICS | ||||||||
Gains Loss On Disposal Of Discontinued Operations | -- | -- | -- | -- | -- | $14.5M | ||
Net Income Discontinuous Operations | -- | -- | -- | -- | -- | $14.5M | ||
Other Gand A | $32.3M | $60.3M | $79.1M | $90.5M | $103.4M | $105.4M | ||
Rent And Landing Fees | $32.3M | -- | -- | -- | -- | -- |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | DNLI | $15.27 | -2.4% | 1.89M |
3 | ||||
4 | ||||
5 | ||||
6 |
Get Denali Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW